Did Gilead just low­er the bar on cru­cial remde­sivir tri­als for Covid-19? Switch­ing end­points, amp­ing up tri­al size stir an­a­lyst­s' fears — and hopes

To say Gilead’s remde­sivir is in the R&D spot­light would be one of the great un­der­state­ments of the year.

The most ad­vanced late-stage an­tivi­ral now in de­vel­op­ment for Covid-19 is seen as a po­ten­tial treat­ment for pop­u­la­tions deeply fright­ened of be­ing killed by the new virus, of­fer­ing a pos­si­ble calm­ing ef­fect for mar­kets where pan­ic runs deep — if the da­ta are pos­i­tive. And that has an­a­lysts read­ing any tea leaves that come their way.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.